The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Abstract
Background Few therapeutic options are available for patients with moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two randomised trials.Methods SUNSHINE and SUNRISE were identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials done in 219 primary sites in 40 countries. Patients aged 18 years old or older with the capacity to provide written informed consent and with moderate-to-severe hidradenitis suppurativa (defined as a total of ≥5 inflammatory lesions affecting ≥2 distinct anatomical areas) for at least 1 year were eligible for inclusion. Included patients also agreed to daily use of topical over-the-counter antiseptics on the areas affected by hidradenitis suppurativa lesions while on study treatment. Patients were excluded if they had 20 or more fistulae at baseline, had ongoing active conditions requiring treatment with prohibited medication (eg, systemic biological immunomodulating treatment, live vaccines, or other investigational treatments), or met other exclusion criteria. In both trials, patients were randomly assigned (1:1:1) by means of interactive response technology to receive subcutaneous secukinumab 300 mg every 2 weeks, subcutaneous secukinumab 300 mg every 4 weeks, or subcutaneous placebo all via a 2 mL prefilled syringe in a double-dummy method as per treatment assignment. The primary endpoint was the proportion of patients with a hidradenitis suppurativa clinical response, defined as a decrease in abscess and inflammatory nodule count by 50% or more with no increase in the number of abscesses or in the number of draining fistulae compared with baseline, at week 16, assessed in the overall population. Hidradenitis suppurativa clinical response was calculated based on the number of abscesses, inflammatory nodules, draining fistulae, total fistulae, and other lesions in the hidradenitis suppurativa affected areas. Safety was assessed by evaluating the presence of adverse events and serious adverse events according to common terminology criteria for adverse events, which were coded using Medical Dictionary for Regulatory Activities terminology. Both the SUNSHINE, NCT03713619, and SUNRISE, NCT03713632, trials are registered with ClinicalTrials.gov.Findings Between Jan 31, 2019, and June 7, 2021, 676 patients were screened for inclusion in the SUNSHINE trial, of whom 541 (80%; 304 [56%] women and 237 [44%] men; mean age 36·1 years [SD 11·7]) were included in the analysis (181 [33%] in the secukinumab every 2 weeks group, 180 [33%] in the secukinumab every 4 weeks group, and 180 [33%] in the placebo group). Between the same recruitment dates, 687 patients were screened for inclusion in the SUNRISE trial, of whom 543 (79%; 306 [56%] women and 237 [44%] men; mean age 36·3 [11·4] years) were included in the analysis (180 [33%] in the secukinumab every 2 weeks group, 180 [33%] in the secukinumab every 4 weeks group, and 183 [34%] in the placebo group). In the SUNSHINE trial, significantly more patients in the secukinumab every 2 weeks group had a hidradenitis suppurativa clinical response (rounded average number of patients with response in 100 imputations, 81·5 [45%] of 181 patients) compared with the placebo group (60·7 [34%] of 180 patients; odds ratio 1·8 [95% CI 1·1-2·7]; p=0·0070). However, there was no significant difference between the number of patients in the secukinumab every 4 weeks group (75·2 [42%] of 180 patients) and the placebo group (1·5 [1·0-2·3]; p=0·042). Compared with the placebo group (57·1 [31%] of 183 patients), significantly more patients in the secukinumab every 2 weeks group (76·2 [42%] of 180 patients; 1·6 [1·1-2·6]; p=0·015) and the secukinumab every 4 weeks group (83·1 [46%] of 180 patients; 1·9 [1·2-3·0]; p=0·0022) had a hidradenitis suppurativa clinical response in the SUNRISE trial. Patient responses were sustained up to the end of the trials at week 52. The most common adverse event by preferred term up to week 16 was headache in both the SUNSHINE (17 [9%] patients in the secukinumab every 2 weeks group, 20 [11%] in the secukinumab every 4 weeks group, and 14 [8%] in the placebo group) and SUNRISE (21 [12%] patients in the secukinumab every 2 weeks group, 17 [9%] in the secukinumab every 4 weeks group, and 15 [8%] in the placebo group) trials. No study-related deaths were reported up to week 16. The safety profile of secukinumab in both trials was consistent with that previously reported, with no new or unexpected safety findings detected.Interpretation When given every 2 weeks, secukinumab was clinically effective at rapidly improving signs and symptoms of hidradenitis suppurativa with a favourable safety profile and with sustained response up to 52 weeks of treatment.Funding Novartis Pharma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the fifth script, the LLM had included data directly from a publication that reported non-integer values for number of events [24].”
From Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models (2024) · cites this paper as [24]
Citations
Cites
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093
Self-citationTwo Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 807
Self-citationSabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Self-citationGoldburg, S. R., Strober, B. E., & Payette, M. J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.090 · Cited by 486
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.068 · Cited by 399
Self-citationDiagnostic delay in hidradenitis suppurativa is a global problem
Saunte, D. M., Boer, J., Stratigos, A., Szepietowski, J. C., Hamzavi, I., Kim, K. H., Zarchi, K., Antoniou, C., Matusiak, L., Lim, H. W., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14038 · Cited by 398
Self-citationDysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Kelly, G., Hughes, R., McGarry, T., Born, M., Adamzik, K., Fitzgerald, R., Lawlor, C., Tobin, A. M., Sweeney, C. M., & Kirby, B. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14075 · Cited by 306
Garg, A., Neuren, E., Cha, D., Kirby, J. S., Ingram, J. R., Jemec, G. B. E., Esmann, S., Thorlacius, L., Villumsen, B., Marmol, V. D., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.1301 · Cited by 291
Self-citationPathophysiology of hidradenitis suppurativa: An update
Prens, E., & Deckers, I. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.07.045 · Cited by 239
The epidemiology of hidradenitis suppurativa*
Ingram, J. R. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19435 · Cited by 223
Cited by
Sabat, R., Alavi, A., Wolk, K., Wortsman, X., McGrath, B., Garg, A., & Szepietowski, J. C. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02475-9 · Cited by 213
Self-citationKimball, A. B., Jemec, G. B. E., Sayed, C. J., Kirby, J. S., Prens, E., Ingram, J. R., Garg, A., Gottlieb, A. B., Szepietowski, J. C., Bechara, F. G., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00101-6 · Cited by 195
Self-citationEuropean S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
Zouboulis, C. C., Bechara, F. G., Benhadou, F., Bettoli, V., Mokoš, Z. B., del Mármol, V., Dolenc‐Voljč, M., Giamarellos‐Bourboulis, E. J., Grimstad, Ø., Guillem, P., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20472 · Cited by 159
Self-citationHidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
Krueger, J. G., Frew, J. W., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E. P., Reich, K., Cullen, E., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad345 · Cited by 132
Self-citationNavarro‐Compán, V., Puig, L., Vidal, S., Ramírez, J., Llamas‐Velasco, M., Fernández‐Carballido, C., Almodóvar, R., Pinto, J., Galíndez‐Aguirregoikoa, E., Zarco, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191782 · Cited by 133
Metadata
- Authors
- Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., Ruëff, F., Pillay Ramaya, L., Reich, A., Lobo, I., Sinclair, R., Passeron, T., Martorell, A., Mendes-Bastos, P., Kokolakis, G., Becherel, P.-A., Wozniak, M. B., Martinez, A. L., Wei, X., Uhlmann, L., Passera, A., Keefe, D., Martin, R., Field, C., Chen, L., Vandemeulebroecke, M., Ravichandran, S., & Muscianisi, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Zealand University Hospital (DK)
- Icahn School of Medicine at Mount Sinai (US)
- Ruhr University Bochum (DE)
- Inserm (FR)
- Lyon 1 Université (FR)
- Ludwig-Maximilians-Universität München (DE)
- University of Rzeszów (PL)
- Sinclair Dermatology (AU)
- Hospital de Manises (ES)
- Humboldt-Universität zu Berlin (DE)
- Novartis (Ireland) (IE)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 401
- Issue
- 10378
- Pages
- 747-761
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4319067669
- Cited by
- 343
- References
- 37
- Citations by year
- 2026: 82 · 2025: 99 · 2024: 100 · 2023: 62
- FWCI
- 94.01
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-02-17)
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
- Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- secukinumab, hidradenitis suppurativa, IL-23 inhibition, biologic therapy, clinical response, abscess, inflammatory nodules, treatment safety, adverse events, dosing interval, sunshine, sunrise, double-dummy design, topical antiseptics, treatment discontinuation
- MeSH terms
- Abscess, Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Male, Treatment Outcome, Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00022-3
- The paper
- Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., Ruëff, F., Pillay Ramaya, L., Reich, A., Lobo, I., Sinclair, R., Passeron, T., Martorell, A., Mendes-Bastos, P., Kokolakis, G., . . . Muscianisi, E. (2023). Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. https://doi.org/10.1016/s0140-6736(23)00022-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.